Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 102.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 750,235 shares of the company’s stock after buying an additional 379,828 shares during the quarter. Point72 Asset Management L.P. owned 2.27% of Lexeo Therapeutics worth $4,937,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Allostery Investments LP bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $33,000. China Universal Asset Management Co. Ltd. bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $46,000. Price T Rowe Associates Inc. MD bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $69,000. SG Americas Securities LLC bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $72,000. Finally, Wells Fargo & Company MN boosted its stake in Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock valued at $73,000 after buying an additional 3,714 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 1.5%

LXEO opened at $3.29 on Tuesday. Lexeo Therapeutics, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The business has a 50-day moving average of $3.08 and a 200-day moving average of $4.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $109.22 million, a PE ratio of -1.04 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19). Equities research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LXEO shares. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. HC Wainwright decreased their price target on Lexeo Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Chardan Capital decreased their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Finally, Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average price target of $20.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.